U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H32N4O3S.ClH
Molecular Weight 481.051
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NUPAFANT HYDROCHLORIDE

SMILES

Cl.CCOC[C@H](CC(C)C)N(C)S(=O)(=O)C1=CC=C(CN2C(C)=NC3=C2C=CN=C3)C=C1

InChI

InChIKey=ZWKDNGFLPQQUPZ-BDQAORGHSA-N
InChI=1S/C23H32N4O3S.ClH/c1-6-30-16-20(13-17(2)3)26(5)31(28,29)21-9-7-19(8-10-21)15-27-18(4)25-22-14-24-12-11-23(22)27;/h7-12,14,17,20H,6,13,15-16H2,1-5H3;1H/t20-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C23H32N4O3S
Molecular Weight 444.59
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Nupafant (BB-960) is a potent platelet activating factor antagonist that is active both orally and intravenously. Nupafant was in phase I clinical trials in the UK for the treatment of ischemia-reperfusion injury, however this compound has since been suspended.

Originator

Approval Year

PubMed

Sample Use Guides

In Vitro Use Guide
Global (whole-heart) delivery of 10 uM nupafant, reduced the incidence of ischaemia-induced VF and widened QT interval without affecting coronary flow. Importantly, lower concentrations (0.1 and 1 uM) had no effect on VF, yet widened QT almost identically to 10 uM nupafant.
Substance Class Chemical
Record UNII
IX7N0W911G
Record Status Validated (UNII)
Record Version